My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 104

    1.

    Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells.

    Peters S, Julien S, Heiduschka P, Grisanti S, Ziemssen F, Adler M, Schraermeyer U, Bartz-Schmidt KU.

    Br J Ophthalmol. 2007 Jun;91(6):827-31. Epub 2006 Dec 19.PMID: 17179166 [PubMed - indexed for MEDLINE]Related articles

    2.

    Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells.

    Spitzer MS, Wallenfels-Thilo B, Sierra A, Yoeruek E, Peters S, Henke-Fahle S, Bartz-Schmidt KU, Szurman P; Tuebingen Bevacizumab Study Group.

    Br J Ophthalmol. 2006 Oct;90(10):1316-21. Epub 2006 May 24.PMID: 16723358 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells.

    Spitzer MS, Yoeruek E, Sierra A, Wallenfels-Thilo B, Schraermeyer U, Spitzer B, Bartz-Schmidt KU, Szurman P.

    Graefes Arch Clin Exp Ophthalmol. 2007 Dec;245(12):1837-42. Epub 2007 Mar 9.PMID: 17347807 [PubMed - indexed for MEDLINE]Related articles

    4.

    Effect of tecogalan sodium on angiogenesis in vitro by choroidal endothelial cells.

    Sakamoto T, Ishibashi T, Kimura H, Yoshikawa H, Spee C, Harris MS, Hinton DR, Ryan SJ.

    Invest Ophthalmol Vis Sci. 1995 May;36(6):1076-83.PMID: 7537258 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Choroidal endothelial cells transmigrate across the retinal pigment epithelium but do not proliferate in response to soluble vascular endothelial growth factor.

    Geisen P, McColm JR, Hartnett ME.

    Exp Eye Res. 2006 Apr;82(4):608-19. Epub 2005 Nov 2.PMID: 16259980 [PubMed - indexed for MEDLINE]Related articles

    6.

    The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.

    Béliveau R, Gingras D, Kruger EA, Lamy S, Sirois P, Simard B, Sirois MG, Tranqui L, Baffert F, Beaulieu E, Dimitriadou V, Pépin MC, Courjal F, Ricard I, Poyet P, Falardeau P, Figg WD, Dupont E.

    Clin Cancer Res. 2002 Apr;8(4):1242-50.PMID: 11948139 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo.

    Lowe J, Araujo J, Yang J, Reich M, Oldendorp A, Shiu V, Quarmby V, Lowman H, Lien S, Gaudreault J, Maia M.

    Exp Eye Res. 2007 Oct;85(4):425-30. Epub 2007 Jun 13.PMID: 17714704 [PubMed - indexed for MEDLINE]Related articles

    8.

    Advanced glycation end products induce choroidal endothelial cell proliferation, matrix metalloproteinase-2 and VEGF upregulation in vitro.

    Hoffmann S, Friedrichs U, Eichler W, Rosenthal A, Wiedemann P.

    Graefes Arch Clin Exp Ophthalmol. 2002 Dec;240(12):996-1002. Epub 2002 Nov 19.PMID: 12483322 [PubMed - indexed for MEDLINE]Related articles

    9.

    Growth-related effects of oxidant-induced stress on cultured RPE and choroidal endothelial cells.

    Eichler W, Reiche A, Yafai Y, Lange J, Wiedemann P.

    Exp Eye Res. 2008 Oct;87(4):342-8. Epub 2008 Jun 29.PMID: 18640112 [PubMed - indexed for MEDLINE]Related articles

    10.

    Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells.

    Carneiro A, Falcão M, Pirraco A, Milheiro-Oliveira P, Falcão-Reis F, Soares R.

    Exp Eye Res. 2009 Mar;88(3):522-7. Epub 2008 Nov 30.PMID: 19135441 [PubMed - indexed for MEDLINE]Related articles

    11.

    Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization.

    Han YS, Lee JE, Jung JW, Lee JS.

    Graefes Arch Clin Exp Ophthalmol. 2009 Apr;247(4):541-8. Epub 2008 Oct 25.PMID: 18953554 [PubMed - indexed for MEDLINE]Related articles

    12.

    Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways.

    Klettner A, Roider J.

    Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4523-7. Epub 2008 Apr 25.PMID: 18441313 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Role of pigment epithelium-derived factor on proliferation and migration of choroidal capillary endothelium induced by vascular endothelial growth factor in vitro.

    Wang FH, Sun XD, Zhang X, Xu X, Zhu Q, Huang JN, Fan Y, Gu Q, Liu HY.

    Chin Med J (Engl). 2007 Sep 5;120(17):1534-8.PMID: 17908464 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Capsiate, a nonpungent capsaicin-like compound, inhibits angiogenesis and vascular permeability via a direct inhibition of Src kinase activity.

    Pyun BJ, Choi S, Lee Y, Kim TW, Min JK, Kim Y, Kim BD, Kim JH, Kim TY, Kim YM, Kwon YG.

    Cancer Res. 2008 Jan 1;68(1):227-35.PMID: 18172315 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Safety profile of bevacizumab on cultured human corneal cells.

    Yoeruek E, Spitzer MS, Tatar O, Aisenbrey S, Bartz-Schmidt KU, Szurman P.

    Cornea. 2007 Sep;26(8):977-82.PMID: 17721300 [PubMed - indexed for MEDLINE]Related articles

    16.

    Interaction between bevacizumab and murine VEGF-A: a reassessment.

    Yu L, Wu X, Cheng Z, Lee CV, LeCouter J, Campa C, Fuh G, Lowman H, Ferrara N.

    Invest Ophthalmol Vis Sci. 2008 Feb;49(2):522-7.PMID: 18234994 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    The effects of growth factors on the proliferation and in vitro angiogenesis of human macular inner choroidal endothelial cells.

    Browning AC, Dua HS, Amoaku WM.

    Br J Ophthalmol. 2008 Jul;92(7):1003-8.PMID: 18577655 [PubMed - indexed for MEDLINE]Related articles

    18.

    Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma.

    Lee SY, Kim DK, Cho JH, Koh JY, Yoon YH.

    Arch Ophthalmol. 2008 Jul;126(7):953-8.PMID: 18625942 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.

    Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D.

    Curr Med Chem. 2006;13(16):1845-57. Review.PMID: 16842197 [PubMed - indexed for MEDLINE]Related articles

    20.

    Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro.

    Wang Y, Fei D, Vanderlaan M, Song A.

    Angiogenesis. 2004;7(4):335-45. Epub 2005 May 9.PMID: 15886877 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity